Modus Therapeutics Updates on Sevuparin Phase 1b Clinical Trial Timelines
STOCKHOLM, SWEDEN – 25 May 2022: Modus Therapeutics Holding AB, a biopharma company focused on the clinical development of its proprietary asset sevuparin for the treatment of sepsis/septic shock and other conditions with systemic inflammation, provides an update on its ongoing Phase 1b LPS-challenge study and its other clinical activities with sevuparin.Modus has observed that the ongoing effects of the Covid-19 pandemic throughout spring have slowed down enrolment for the Phase 1b trial, causing a delay to the anticipated timelines. This is largely attributed to subjects being unable to